A new multicenter study shows use of Medtronic’s InterStim Therapy via sacral nerve stimulation reduced incontinent episodes and improved quality of life in most patients with chronic fecal ...

ZANESVILLE – Dr. Mitesh Parekh, a urogynecologist with Genesis Urogynecology, has been recognized by Medtronic, a medical device company, for outstanding contribution in positively impacting the lives ...

The FDA has approved Medtronic plc’s next-generation sacral neuromodulation (SNM) system, Interstim X, giving patients a recharge-free option with a 10-year+ lifespan. This newest member of the ...

announced today that newly published data from a multicenter, prospective trial show that sacral nerve stimulation using Medtronic InterStim® Therapy reduced incontinent episodes and increased quality ...

WASHINGTON, D.C.—Sacral neuromodulation with InterStim Therapy is safe and well tolerated as a treatment for patients with overactive bladder and those with urinary retention, French investigators ...

ELITE Study Designed to Confirm Long-Term Safety, Efficacy and Patient Benefit of Sacral Neuromodulation with the InterStim™ Micro System for Treatment of Overactive Bladder, Fecal Incontinence and ...

This past spring, Medtronic Inc. (Minneapolis) announced plans to significantly boost its investment in clinical trials for the company's neurological therapies. Throughout Medtronic's fiscal 2007, ...

The FDA has approved an app-based smart programming device used to discreetly and easily control implants treating for overactive bladder (OAB), chronic fecal incontinence (FI) and non-obstructive ...

Medtronic Inc. said Friday that it has received Food and Drug Administration approval for an implantable device to help patients better control their bowel movements. The product, called InterStim ...